deltatrials

Chronic lymphocytic leukemia Trials in Perugia, Italy

Conditions / Chronic lymphocytic leukemia / Perugia, Italy

Chronic lymphocytic leukemia has been the subject of sustained clinical investigation across multiple research sites.

12 total trials for this combination

Showing top 10 of 12 trials

Trials

NCT ID Title Status Phase
NCT02582320 Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program COMPLETED
NCT07218341 A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma RECRUITING
NCT04282811 Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy RECRUITING
NCT04666038 Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) ACTIVE_NOT_RECRUITING
NCT06291220 A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) ACTIVE_NOT_RECRUITING PHASE1
NCT06205498 Acalabrutinib Real World Italian obSErvational Study -ARISE ACTIVE_NOT_RECRUITING
NCT05153330 Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL TERMINATED PHASE1
NCT06846671 A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors RECRUITING
NCT06588478 A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma RECRUITING PHASE2
NCT05023980 A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) ACTIVE_NOT_RECRUITING PHASE3

Related Pages